WSJ cited DealForma data showing that China and Hong Kong companies accounted for 50% of large pharma in-licensing deals with at least $50 million upfront so far this year, underscoring rising global pharma interest in China-originated assets. Read it here
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive
